Lorlatinib Induced Non-cardiogenic Pulmonary Edema: A Case Report

被引：0

作者：

Matsuoka, Suzuka ^{[1
]}

Watanabe, Hiromi ^{[1
]}

Inoue, Tomoyoshi ^{[1
]}

Takigawa, Yuki ^{[1
]}

Kudo, Kenichiro ^{[1
]}

Sato, Akiko ^{[1
]}

Sato, Ken ^{[1
]}

Fujiwara, Keiichi ^{[1
]}

Shibayama, Takuo ^{[1
]}

机构：

[1] NHO Okayama Med Ctr, Dept Resp Med, Okayama, Japan

来源：

INTERNAL MEDICINE | 2025年

关键词：

lorlatinib; ALK-positive lung adenocarcinoma; non-cardiogenic pulmonary edema; EGFR;

D O I：

10.2169/internalmedicine.5156-24

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 71-year-old woman was diagnosed with anaplastic lymphoma kinase (ALK)-positive metastatic lung adenocarcinoma staged as cT1cN3M1c (8th edition). Treatment with lorlatinib (100 mg) was initiated on a daily basis. Three weeks after the first dose, the patient was hospitalized because of lorlatinib-induced noncardiogenic pulmonary edema. The patient's condition improved with diuretic therapy, and lorlatinib was rechallenged at a reduced dose. Follow-up computed tomography revealed a partial response. This is a rare case of non-cardiogenic pulmonary edema as an adverse effect of lorlatinib.

引用

页数：4

共 50 条

[31] Small Cell Transformation After Lorlatinib ALK Resistance - A Case Report with Clonal Evolution
Xu, X.
Fan, Y.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S485 - S485
[32] Acute pulmonary edema induced by non-ionic low-osmolar radiographic contrast media
Pincet, Laurence
Lecca, Gabriele
OPEN ACCESS EMERGENCY MEDICINE, 2018, 10 : 75 - 79
[33] Effective treatment of advanced lung adenocarcinoma with paraneoplastic leukemoid reaction with Lorlatinib: a case report
Niu, Ruiqi
Zhang, Yiruo
Pang, Jingdan
Zhou, Qing
Lei, Yu
Du, Yingying
FRONTIERS IN ONCOLOGY, 2024, 14
[34] Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
Kashizaki, Fumihiro
Tanaka, Arihito
Sekido, Yasutomo
JOURNAL OF MEDICAL CASE REPORTS, 2022, 16 (01)
[35] Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
Fumihiro Kashizaki
Arihito Tanaka
Yasutomo Sekido
Journal of Medical Case Reports, 16
[36] ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
Li, Huihui
Song, Tianqi
Xu, Xiaoling
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
[37] Fatal noncardiogenic pulmonary edema related to nonionic, iso-osmolar iodine contrast medium: one case report
Kun-ming Yi
Xue Li
BMC Pulmonary Medicine, 22
[38] Fatal noncardiogenic pulmonary edema related to nonionic, iso-osmolar iodine contrast medium: one case report
Yi, Kun-Ming
Li, Xue
BMC PULMONARY MEDICINE, 2022, 22 (01)
[39] Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib
Shahab, Shubin W. W.
Schniederjan, Matthew
Vega, Jose Velazquez
Little, Stephen
Reisner, Andrew
MacDonald, Tobey
Aguilera, Dolly
FRONTIERS IN ONCOLOGY, 2023, 13
[40] Pathological complete response to neoadjuvant lorlatinib in a patient with stage IIIA ALK-positive non-small cell lung cancer: a case report
Lu, Li
Cao, Zhengqi
Wang, Anni
Chen, Lixuan
Sun, Jing
Li, Ziming
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (07) : 1742 - 1748

← 1 2 3 4 5 →